Higher defibrotide doses may help severe transplant complication
NCT ID NCT05987124
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether increasing the dose of defibrotide can safely help patients with a serious liver condition called SOS/VOD that occurs after a stem cell transplant. The condition can damage the kidneys and lungs and often does not improve with standard defibrotide doses. Researchers will enroll 20 patients and gradually raise their dose every few days, monitoring for side effects and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
defibrotide (Defitelio)
What this could lead to
If successful, this could provide a treatment option for patients with severe liver SOS/VOD after stem cell transplant who are not helped by standard doses.
What could go wrong
This is a small, early-phase trial with only 20 participants. Higher doses may increase bleeding risk, and it is unclear if they will improve survival or organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SINUSOIDAL OBSTRUCTION SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical College
RECRUITINGVallhala, New York, 10595, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact